The role of proliferation signal inhibitors in post-transplant malignancies

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL. 1, 2007, Pages

  Gutiérrez Dalmau, Álex ^a   Campistol, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer; Everolimus; Proliferation signal inhibitors mTOR inhibitors; Sirolimus; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CELL ADHESION MOLECULE; CISPLATIN; CYCLOSPORIN A; EVEROLIMUS; FLUOROURACIL; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; TEMSIROLIMUS; VASCULOTROPIN; CALCINEURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PTEN PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; METASTASIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; SKIN CANCER; SOLID TUMOR; UPREGULATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CALCINEURIN; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34250156366     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm084     Document Type: Article

References (25)

1. Koehl GE, Schlitt HJ, Geissler EK. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplant Rev 2005; 19: 20-31
2. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980
3. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005; 7: 356-368
4. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319
5. Shi Y, Gera J, Hu L et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027-5034
6. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759
7. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717
8. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoprpliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4285-4290
9. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601
10. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572
11. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135
12. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-261
13. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-449
14. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
15. Morales JM, Campistol JM, Kreis H et al. Sirolimus-based therapy with or without cyclosporine: Long-term follow-up in renal transplant patients. Abstract 775. American Transplant Congress, Washington D.C., May 30 to June 4, 2003.
16. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
17. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855-857
18. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323
19. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762
20. Gonzalez-Lopez MA, Rodrigo E, Gonzalez-Vela MC et al. Posttransplant Kaposi's sarcoma restricted to the site of a previous deep vein thrombosis: Abrupt onset after withdrawal of sirolimus. Dermatology 2006; 213: 30-33
21. Tabernero J, Rojo F, Burris H et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol 2005; 23: Abstract 3007
22. Doherty L, Gigas DC, Kesari S et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006; 67: 156-158
23. Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: The RAD001 (Everolimus)-letrozole clinical program. Semin Oncol 2006; 33: S18-S25
24. Chollet P, Abrial C, Tacca O et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7: 336-338
25. Campistol JM, Albanell J, Arns WA et al. Clinical guidance on the use of proliferation signal inhibitors in the management of post-transplant malignancies. Nephrol Dial Transplant 2007; 22 [Suppl 1]: I36-i41